Upload
rudy-asbridge
View
215
Download
0
Embed Size (px)
Citation preview
Professor Helen ReesExecutive Director, WRHI, Wits Reproductive Health and HIV Institute &
Ad Hominem Professor, Department of Obstetrics and Gynaecology,University of Witwatersrand
Honorary Professor, London School of Hygiene & Tropical Medicine
Contraception and HIV
“Love is the answer, but while you are waiting for the answer, sex raises some pretty good
questions.” Woody Allen
Women have a right to decide whether they want to become pregnant and bear children irrespective of their HIV status.Women must be enabled to make informed, voluntary decisions about contraception and then receive a safe, effective method of her choice.
Trends in Maternal Mortality Ratios
WHO 2010
Avoidance of unintended pregnancy is most effective way of reducing number of deaths: 40% of global deaths averted in 2008 by contraception (Darroch & Singh 2011: Ahmed et al 2011)
Over 150 million women use hormonal contraception worldwide, primarily oral
contraceptives (OCs) and injectable depot-medroxyprogesterone acetate (DMPA).
The overall demand for contraception is increasing
17 12 14 1018
11
59 6954 60 41 59
14 20
26 24
0
20
40
60
80
100
1990-1995
2000-2005
1990-1995
2000-2005
1990-1995
2000-2005
1990-1995
2000-2005
Unmet need Met need
% of married women aged 15–49
Latin America & Caribbean
North Africa & West Asia
South & Southeast Asia
Sub-Saharan Africa
Method mix: among currently married (CM) & sexually active not married (NM) women ,
% using specific method
CM
NM
CM
NM
CM
NM
CM
NM
CM
NM
CM
NM
Kenya 2008-09
Lesotho 2001 Malawi 2010 Swaziland 2006
Tanzania 2010
Zambia 2007
0tan28a566028
0tan9a56609
0tan19a566019
0tan29a566029
0tan9a56609
0tan19a566019
0tan29a566029
0tan9a56609
0tan19a566019
0tan29a566029
0tan10a566010
Other
Condom
Pill
Injectable
Country and Survey Year
Pre
vale
nce
(%)
Lesotho 2009
Source: Demographic and Health Surveys 2006-1010
6 7 1324 25
38 43 44
5 7 10 12
2811
23
18 16
96 11
2621 19
36 2534 21 24
1329
12
2013
1018 7
20
5 6
20
197 27 11
0
20
40
60
80
100
Do
min
ica
n R
ep
ub
lic
Co
lom
bia
Pe
ru
Ke
ny
a
Gh
an
a
Ug
an
da
Ma
li
Bo
liv
ia
Do
min
ica
n R
ep
ub
lic
Co
lom
bia
Pe
ru
Ke
ny
a
Ug
an
da
Gh
an
a
Ma
li
Bo
liv
ia
Lack of knowledge Health/side effects Opposition
The importance of some reasons for non-use has changed over time
% of married women aged 15–49 with unmet need
1986–1989 2002–2005
Adherence in contraceptive use
Status 1 year 2 years(%) n (%) n
Continued 42 79 21 39Lost to follow up
30 57 35 67
Discontinued 28 48 41 78Withdrew 2 5 2 5
189 progestin injectable users followed up for 2 years in family planning clinic in Soweto
Of those who discontinued: • 40% ‘taking a break’• >50% complained of side effects
Beksinska, Rees et al. Contraception 64(2001)
Adult female HIV prevalence
The importance of contraception as part of PMTCT
Prevention of HIV in women, especially young women
Prevention of unintended pregnancies in HIV-infected women
Prevention of transmission from an HIV-infected woman to her infant
Support for mother and family
Element 1 Element 2 Element 3 Element 4
.Significant contribution coming from the provision of contraceptive information, services and counselling.
Pregnancy Intentions & Incidence Study: Prospective Cohort Study of HIV Positive Women on ART in South Africa, Swartz S, Black V et al
• 851 non-pregnant women on different ARV regimens recruited from 4 WRHI-supported sites between August 2009 – January 2010
Contraceptive Use n (%)Consistent condom use 540 (63.5%)
Injectables 175 (20.6%)
Oral contraceptives 45 (5.3%)
Implants 4 (0.5%)IUDs 1 (0.1%)Dual (Condoms+HC) 131 (15.4%)
Overall 631 (74.1%)
How far can we push Dual Method use? Condom use at last sexual intercourse, amongst injectable
contraception users
Lesotho 2009 Malawi 2004 Namibia 2006-07
Swaziland 2006-07
Zambia 2007 Zimbabwe 2005-06
0tan28a566028
0tan4a56604
0tan9a56609
0tan14a566014
0tan19a566019
0tan24a566024
0tan29a566029
0tan4a56604
0tan9a56609
0tan14a566014
0tan19a566019
Country and Survey Date
Pre
vale
nce
(%)
Source: Demographic and Health Surveys 2004-1010
Glass ceiling?
Contraception and HIV: What to consider
Women at riskfor HIV
Acquisition
Women infected with HIV
Infectiousness Disease progression
Drug interactions
Prevention
Contraception and HIV: How WHO guidance has worked…
Acquisition Infectiousness Disease progression
WHO’s Medical Eligibility Criteria for Contraceptive Use
Research
WHO consultants & committee:
Systematic review, Grading of scientific evidence
The evidence is used to develop international recommendations and includes expert opinion where evidence is not available
International recommendations are adapted for national guidelines
Job aids (tools) are developed
Eligibility Criteria for Contraceptive use: WHO Classifications
Definition
Classification of Conditions Definition
1 No restriction on use
2 Benefits generally outweigh risks
3 Risks generally outweigh benefits
4 Unacceptable health risk
WHO Conclusions - 2008
• “Intermediate” level of evidence
• COC – Category 1 - “No Restriction”
• DMPA – Category 1 for women at risk of HIV – Category 2 for youth (bone concerns) “Advantages Outweigh Risks”
Source: WHO Medical Eligibility Criteria (2008)
Hormonal contraceptive use for women at high risk of HIV
DMPA – Category 1 - No Restriction
Balance of evidence suggests no association between progestin contraceptives and HIV acquisition, although studies of DMPA use conducted among higher risk populations have repeated inconsistent findings
“Intermediate” level of evidence
Source: WHO Medical Eligibility Criteria fourth edition 2009
ProgesteroneNature Med., 1996
DMPAJ. Infect. Dis., 2004
DMPAVirology, 2006
- Genescà et al., J. Med. Primatol. , 2007- Mascola et al., Nature Med. 2000- Veazey et al., Proc. Natl. Acad. Sci. USA 2008- Pal et al., Virology 2009- Turville et al., PLoS One 2008
Reported effect of progesterone or its derivatives References
Inhibition of IgG and IgA production and trans-epithelial transport (78;87-96;129-134)
Decreased frequency of antibody-secreting cells in women and female macaques (90;96)
Decreased specific IgG and IgA responses following mucosal immunization with attenuated HSV-2; induction of permissive conditions for intravaginal infection of mice with HSV-2 and Chlamydia trachomatis
(132-134)
Inhibition of T cell responses and cytotoxic activity (139-143;147)
Inhibition of perforin expression in T cells (140-142;144-146)
Decreased proliferation and Th1-type cytokine production by VZV-specific CD4+ T cells in HIV-1 patients (148)
Altered migration and decreased activity of NK cells (105;106;106;135;159;251;252)
PIBF-mediated shift towards Th2 cytokine expression profile (133;149-154)Altered migration and infiltration of lymphocytes, macrophages, and NK cells into the female genital tract tissues (117;118;157;158;183;191;253)
Increased expression of CCR5 on cervical CD4+ lymphocytes (81;82)
Thinning of cervico-vaginal epithelium in rhesus macaques (42;66)
Increased frequency of Langerhans cells in vaginal epithelium (76;77)
Regulation of HIV replication and LTR activity (254)
Suppression of IL-1, IL-2, and IL-6 release by human lymphocytes (148;177)
Inhibition of TLR-9-induced IFN-α production by human and mouse pDCs (162)
Increased shedding of HIV-1 in the genital tract (35-37)
Decreased FcγR expression on monocytes (159;160)Decreased vaginal colonization with H2O2-producing Lactobacillus (70)
Reported effects of progesterone and its derivatives on immune system & HIV-1 infection.
Hel Z. et al., Endocrine Rev., 2010, 79-97.
Hormones and HIV Possible Mechanisms
• Vaginal and cervical epithelium (ectopy, etc.)• Cervical mucus• Menstrual patterns • Vaginal and cervical immunology • Viral (HIV) replication• Acquisition of other STI
0.1 1 10Protective Harmful
Studies of Injectables & HIV Acquisition
Source: Adapted from Polis (2011)
Kumwenda 2008
Ungchusak 1996
Feldblum 2010
Heffron 2011
Bulterys 1994
Baeten 2007
Watson-Jones 2009
Kilmarx 1998
Morrison 2010
Myer 2007
Reid 2010
Kiddugavu 2003
Kleinschmidt 2007
Kapiga 1998
Prospective cohort study of 3790 HIV- 1 discordant couples from East and southern
Africa
Renee Heffron, Deborah Donnell, Helen Rees, Connie Celum, Edwin Were, Nelly Mugo, Guy de Bruyn, Edith
Nakku- Joloba, Kenneth Ngure, James Kiarie and Jared ‐Baeten
July 2011 – Partners in Prevention Study on HIV acquisition and HC presented at IAS
Conference, Rome
Contraception and HIV acquisition from men to women
Adjusted Cox PH Regression analysis
HIV incidence per 100 person years
HR (95% CI) P-value
No hormonal contraception
3.78 1.00
Any hormonal contraception
6.61 1.98(1.06 – 3.68)
0.03
Injectables 6.85 2.05(1.04 – 4.04)
0.04
Oral contraceptives 5.94 1.80(0.55 – 5.82)
0.33
21.2% of women used HC at least once during study
Contraception and HIV acquisition from women to men
Adjusted Cox PH Regression analysis
HIV incidence per 100 person years
HR (95% CI) P-value
No hormonal contraception
1.51 1.00
Any hormonal contraception
2.61 1.97 (1.12 – 3.45) 0.02
Injectables 2.64 1.95 (1.06 – 3.55) 0.03
Oral contraceptives 2.50 2.09 (0.75 – 5.84) 0.16
Conclusion
• Mounting evidence that hormonal contraceptives – particularly injectable methods - increase a woman’s risk of acquiring HIV-1
• First study to demonstrate that hormonal contraceptives increase an HIV 1 infected ‐woman’s risk of transmitting HIV 1 to her ‐partner
The Dilemma for an Uninfected Woman
• If she uses DMPA, • Less risk of pregnancy• More risk of HIV acquisition
• If she stops DMPA• Does she have other contraceptive options?• If not, she may become pregnant • More risk of HIV acquisition• More risk of pregnancy morbidity & mortality• Unwanted pregnancy may have worse infant outcomes
The Dilemma for the Infected woman
• If she uses hormonal contraception• Less risk of pregnancy• More risk of HIV transmission to partner
• If she stops hormonal methods• Does she have other contraceptive options?• If not she may become pregnant • More risk of HIV transmission to partner• More risk of pregnancy Morbidity & Mortality• Potential for transmission to infant• Unwanted HIV infected babies have higher morbidity and
mortality than wanted infants
0.1 1 10Protective Harmful
Studies of Injectables & HIV Acquisition
Source: Adapted from Polis (2011)
Kumwenda 2008
Ungchusak 1996
Feldblum 2010
Heffron 2011
Bulterys 1994
Baeten 2007
Watson-Jones 2009
Kilmarx 1998
Morrison 2010
Myer 2007
Reid 2010
Kiddugavu 2003
Kleinschmidt 2007
Kapiga 1998
WHO Expert Consultation on HC and HIV
• January 2012, Geneva, 75 participants from 18 countries
– HIV Acquisition– HIV Transmission– HIV Progression
• GRADE rating of the evidence• Discussion of MEC criteria• Programmatic implications• Research agenda
WHO Consultation – GRADE Rating
• HC/HIV progression evidence• 1 RCT, 6 cohort studies• Rated “low overall quality”• No change from Category 1
WHO Consultation – GRADE Rating
• HC/HIV transmission evidence• Rated “low overall quality”• No change from Category 1
WHO Consultation – GRADE Rating
• HC/HIV acquisition evidence• 8 cohort studies met minimum quality
criteria• Rated “low overall quality” but better
studies tended towards harm • Major focus of meeting
Contraception and HIV acquisition from men to women
Adjusted Cox PH Regression analysis
HIV incidence per 100 person years
HR (95% CI) P-value
No hormonal contraception
3.78 1.00
Any hormonal contraception
6.61 1.98(1.06 – 3.68)
0.03
Injectables 6.85 2.05(1.04 – 4.04)
0.04
Oral contraceptives 5.94 1.80(0.55 – 5.82)
0.33
21.2% of women used HC at least once during study
The Great Debate
Observational dataPossible selection biasPotential for Confounding Not always primary study endpointHC use not always well documentedSelf reported condom use unreliableCondom use differed between non-HC arms and HC arms
Progestin injectables and HIV acquisition: The Great debate
1. If left an MEC 1 – no change implies that the data are not convincing enough to support even theoretical concerns about injectable progestins and HIV acquisition
2. If moved to MEC 2 – a change implies that there are theoretical concerns which still allows use but if misunderstood might scare women and jeopardize global use without many alternatives being available
3. The meeting was divided between 1 & 2
The WHO Statement – February 2012
The WHO statement on Progestin-only injectables and HIV acquisition, 2012
………the group concluded that the World Health Organization should continue to recommend that there are no restrictions (MEC Category 1) on the use of any hormonal contraceptive method for women living with HIV or at high risk of HIV. However…..
……..because of the inconclusive nature of the body of evidence on possible increased risk of HIV acquisition, women using progestogen-only injectable contraception should be strongly advised to also use condoms and other preventive measures.
The group further wished to draw the attention of policy-makers and programme managers to the potential seriousness of the issue and the complex balance of risks and benefits.
The WHO statement on Progestin-only injectables and HIV acquisition, 2012
What then happened……
• Some activists, women's organisations and journalists said they did not understand the Category ‘1’ and the clarification
• Requested clarity on the messaging that should be given to women users
• Some researchers and donors considering an RCT as a definitive study
• Widespread calls for increasing the method mix in developing countries
• And the modellers are involved……
Where does high HIV prevalence coincide with high use of injectable hormonal contraceptives?
HIV prevalence among 15-49 year-old women*
The overlap between use of injectables and HIV prevalence
HIV: ‘high’ = > 1%; IHC: ‘high’ = upper quartile.
Injectable hormonal contraceptive use among 15-49 year-old women
*Adult HIV prevalence given for China.
From: AR Butler, JA Smith, D Stanton, TB Hallett. The global impact of an interaction between injectable hormonal contraception and HIV risk (subm.).
Number of HIV infections attributable to hypothesised IHC-HIV interaction per year
Regions with high HIV incidence and high IHC use have the most HIV infections attributable to use of injectable hormonal contraceptives
From: AR Butler, JA Smith, D Stanton, TB Hallett. The global impact of an interaction between injectable hormonal contraception and HIV risk (subm.)
Net effect: balance of reduced AIDS deaths & increased maternal deaths
Absolute change in the number of maternal and AIDS deaths on cessation of IHC use
Maximum benefits of stopping or reducing HC in regions of high HIV incidence and low maternal mortalityIncrease in total number of deaths in areas of high HC use and high maternal mortality
From: AR Butler, JA Smith, D Stanton, TB Hallett. The global impact of an interaction between injectable hormonal contraception and HIV risk (subm.)
And WHO went further to clarify its guidance
Based on current evidence, family planningprogrammes delivering services to women atrisk of, or living with, HIV infection can continueto offer all methods of hormonal contraception.However, as none of these methods protectsagainst HIV, the use of condoms or other HIVpreventive measures should always be stronglyrecommended.
WHO’s programmatic and research recommendations
Provide easy-to-understand and comprehensiveinformation to women and their partners aboutthe benefits of contraceptive options available tothem as well as any associated risks, includinginformation regarding the inconclusive nature ofthe evidence on possible increased risk of HIVacquisition among women using progestogen onlyinjectables.
WHO’s programmatic and research recommendations
WHO Recommendations: Research • Produce definitive epidemiological evidence about
HC and HIV acquisition, transmission & disease progression, evaluating longer-acting methods (e.g. implants, IUDs, injectables) & newer methods not previously included
• An RCT?
A Randomised Controlled Trial?
If millions of men were on a high dose of a first generation statin when newer statins with the same efficacy and fewer side effects was available, and the higher dose made men……
• Put on weight• Made their hair temporarily stop growing• And it took 9 months to return to normal• AND may possibly increase HIV risk
How long would the marketplace tolerate this?
From a Women’s health perspective……
Thank You• Ward Cates• Jenny Smith• Tim Hallett• John Cleland • Ellen Crabtree• Chelsea Polis• Vivian Black• Sharon Phillips• Mary Lyn Gaffield• Mitchell Warren• Charlie Morrison• Maggie Kilbourne-Brook• Zdenek Hel• Melanie Pleanar